Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Abbott Laboratories
(NY:
ABT
)
112.69
+0.59 (+0.53%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Abbott Laboratories
DexCom Clears Base, Wall Street Eyes Double-Digit Earnings Growth
June 21, 2023
DexCom's G7 glucose-monitoring solution is driving revenue growth at the company. Analysts expect strong double-digit EPS growth this year and next.
Via
MarketBeat
Looking At Abbott Laboratories's Recent Unusual Options Activity
June 20, 2023
Via
Benzinga
After FDA Rejection, Surmodics' SurVeil Drug-Coated Balloon Scores FDA Approval
June 20, 2023
The FDA has approved Surmodics Inc's (NASDAQ: SRDX) SurVeil drug-coated balloon (DCB), a next-generation device
Via
Benzinga
3 Passive Income Stocks to Hold for the Next 20 Years
June 20, 2023
These three stocks are likely to keep increasing their dividends over years or even decades.
Via
The Motley Fool
Here's How Much $1000 Invested In Abbott Laboratories 10 Years Ago Would Be Worth Today
June 16, 2023
Via
Benzinga
Second Time May Be a Charm: Analyst Is Bullish As Surmodics Resubmits SurVeil DCB Application
June 13, 2023
In an investor presentation, Surmodics Inc (NASDAQ: SRDX) said it submitte
Via
Benzinga
Looking At Abbott Laboratories's Recent Unusual Options Activity
June 06, 2023
Via
Benzinga
Looking At Abbott Laboratories's Recent Unusual Options Activity
May 23, 2023
Via
Benzinga
(ABT) - Analyzing Abbott Laboratories's Short Interest
May 16, 2023
Via
Benzinga
2 Dividend Kings Down 12% and 14% You'll Regret Not Buying on The Dip
June 04, 2023
Recent troubles won't stop these companies' long-term trajectories.
Via
The Motley Fool
Mark Cuban Helping Lower Cost Of Bestselling Humira With Cost Plus Drug Company: 'The Game Just Changed'
June 01, 2023
One of the bestselling medical drugs of all time has come off patent. The result could mean lower costs for those who need the drug as a treatment option. Enter Mark Cuban and his Cost Plus Drug...
Via
Benzinga
Intuitive Surgical Gives Buying Opportunity Off Its 52 Week Highs
May 30, 2023
Intuitive Surgical (NASDAQ: ISRG) manufactures the revolutionary da Vinci Surgical System, the leader in robotic-assisted surgery systems. Da Vinci is turning
Via
MarketBeat
Exposures
COVID-19
Product Safety
Nvidia Chief Flags Dangers To US Chips Act, Disney, Shell, Gucci Allegedly Used Worthless Carbon Credits, Microsoft's Daring Attempt to Outshine Google In Search Game: Today's Top Stories
May 24, 2023
Benzinga
Via
Benzinga
A Look Into Abbott Laboratories Inc's Price Over Earnings
May 15, 2023
Via
Benzinga
Abbott Laboratories Unusual Options Activity For May 10
May 10, 2023
Via
Benzinga
Is There Collusion in the Baby-Formula Industry?: FTC Scrutinizes State Contracts Bidding Process
May 24, 2023
Via
Benzinga
New Data Out Of Cleveland Clinic Shows BioSig PURE EP May Be Used For More Precise Approach For $6 Billion Annual Atrial Fibrillation Market
May 24, 2023
Cleveland Clinic researchers presented data from three new studies involving BioSig Technologies’ (NASDAQ: BSGM) proprietary PURE EP Platform at the annual Heart Rhythm 2023 meeting in Ne
Via
Benzinga
Abbott's Baby Formula Brouhaha: Judge Says No Harm, No Foul in Contamination Controversy
May 23, 2023
U.S. District Judge Matthew Kennelly in Chicago dismissed claims by parents pursuing only "economic loss" claims related to Abbott Laboratories (NYSE: ABT) Similac and other formulas that they said had...
Via
Benzinga
Stereotaxis, Abbott Ink Pact To Combine Mapping & Robotic Tech: FDA Approves Abbott's Next-Gen Abalation Catheter
May 19, 2023
Stereotaxis Inc (NYSE: STXS) shares are gaining after the company announced a global collaboration with Abbott Laboratories (NYSE: ABT) to integrate Abbott's EnSite X EP System with Stereotaxis' <
Via
Benzinga
Back Off, Chronic Pain! FDA Nods for Abbott's Spinal Cord Stimulation Devices
May 16, 2023
The FDA approved Abbott Laboratories (NYSE: ABT) spinal cord stimulation (SCS) devices for chronic back pain in people who have not had or are not eligible to receive back surgery, known as
Via
Benzinga
Here's How Much You Would Have Made Owning Abbott Laboratories Stock In The Last 10 Years
May 05, 2023
Via
Benzinga
Looking At Abbott Laboratories's Recent Unusual Options Activity
April 28, 2023
Via
Benzinga
Got $1,000? 2 Top Dividend Stocks to Buy Now
April 28, 2023
Passive income can add to your stock market winnings.
Via
The Motley Fool
Claims of PediaSure Boosting Children's Height Challenged in Lawsuit Against Abbott Laboratories
May 16, 2023
A New York City woman has reportedly sued Abbott Laboratories (NYSE: ABT), accusing them of misleading consumers into believing its PediaSure nutrition drinks were "clinically proven" to increase...
Via
Benzinga
Investing for the Long-Term? Here are 7 Must-Have Dividend Stocks
May 14, 2023
Here are seven must-have dividend stocks for long-term investing that you can consider for your dividend stock portfolio.
Via
InvestorPlace
Cramer Asks Investors To Focus On Individual Stocks Over Macro Strategies: Says Don't 'Miss The Trees For The Forest'
May 09, 2023
Via
Benzinga
3 Dividend Stock Warning Signs That Could Portend Trouble
May 06, 2023
Recognizing these red flags will help you avoid investing in weaker businesses.
Via
The Motley Fool
Is Dexcom a Good Stock to Buy Now?
May 02, 2023
A poorly received first-quarter earnings report has investors wondering if this stock's best days are behind it.
Via
The Motley Fool
If You Invested $100 In This Stock 10 Years Ago, You Would Have $300 Today
April 27, 2023
Via
Benzinga
3 Stocks to Buy Before They Soar to New Heights in 2023
May 01, 2023
Here are three stocks to buy, for investors looking for companies on the cusp of a potential breakout driven by secular growth catalysts.
Via
InvestorPlace
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.